Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Down 85.7% in March

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 10,600 shares, a decrease of 85.7% from the February 29th total of 74,000 shares. Based on an average trading volume of 1,520,000 shares, the days-to-cover ratio is currently 0.0 days.

Provectus Biopharmaceuticals Stock Down 8.5 %

OTCMKTS PVCT traded down $0.02 on Thursday, hitting $0.18. 236,436 shares of the company were exchanged, compared to its average volume of 313,251. Provectus Biopharmaceuticals has a 12 month low of $0.06 and a 12 month high of $0.22. The stock has a fifty day moving average of $0.15 and a 200-day moving average of $0.12.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis.